All In Biotech

Drug Trial Radar · NCT00064428

OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction

An International Randomized Study Evaluating the Efficacy and Safety of Fondaparinux Versus Control Therapy in a Broad Range of Patients With ST Segment Elevation Acute Myocardial Infarction.

Last checked: Nov 20, 2026Latest source record: Sep 23, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 12,092 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

12,092

Actual

Start

Aug 2003

Primary completion

Feb 2006

Study completion Feb 2006

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
Sanofi
First posted
Oct 17, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double blindcontrolled, parallel group, multi-center, multinational study of fondaparinux vs. control in patients with STEMI (ST segment myocardial infarction) randomized within 24 hours of the onset of symptoms.

Conditions

  • Thromboembolism

Interventions

  • fondaparinux - UFH not indicatedDrug

    2.5mg od, sc (1st dose IV) x 8 days or discharge

  • Control - UFH not indicatedOther

    Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge

  • Fondaparinux - UFH indicatedDrug

    2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus x 24-48 hr infusion

  • Control - UFHDrug

    UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Death or recurrent myocardial infarctionTime frame: up to day 30
  2. Severe hemorrhageTime frame: up to Day 9

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.